IL309036A - Line-1 inhibitors as cognitive enhancers - Google Patents
Line-1 inhibitors as cognitive enhancersInfo
- Publication number
- IL309036A IL309036A IL309036A IL30903623A IL309036A IL 309036 A IL309036 A IL 309036A IL 309036 A IL309036 A IL 309036A IL 30903623 A IL30903623 A IL 30903623A IL 309036 A IL309036 A IL 309036A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitors
- line
- cognitive enhancers
- cognitive
- enhancers
- Prior art date
Links
- 239000002475 cognitive enhancer Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163197015P | 2021-06-04 | 2021-06-04 | |
| PCT/US2022/032120 WO2022256625A1 (en) | 2021-06-04 | 2022-06-03 | Line-1 inhibitors as cognitive enhancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309036A true IL309036A (en) | 2024-02-01 |
Family
ID=84323626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309036A IL309036A (en) | 2021-06-04 | 2022-06-03 | Line-1 inhibitors as cognitive enhancers |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240285664A1 (enExample) |
| EP (1) | EP4346835A4 (enExample) |
| JP (1) | JP2024520132A (enExample) |
| KR (1) | KR20240017910A (enExample) |
| CN (1) | CN117813096A (enExample) |
| AU (1) | AU2022283915A1 (enExample) |
| CA (1) | CA3221190A1 (enExample) |
| IL (1) | IL309036A (enExample) |
| MX (1) | MX2023014381A (enExample) |
| WO (1) | WO2022256625A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4358968A4 (en) * | 2021-06-22 | 2025-05-07 | Rome Therapeutics, Inc. | 4-ETHINYL-3-HYDROXY-TETRAHYDROFURANYL ADENINE PHOSPHORAMIDATE AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES |
| EP4482498A4 (en) * | 2022-02-22 | 2026-02-25 | Rome Therapeutics Inc | METHODS OF TREATING MEDICAL PROBLEMS USING CENSAVUDINE OR A COMBINATION COMPOUND |
| US20250186475A1 (en) * | 2022-03-15 | 2025-06-12 | Rome Therapeutics, Inc. | Methods of treating medical conditions using islatravir or a related compound |
| WO2024107850A1 (en) * | 2022-11-15 | 2024-05-23 | Rome Therapeutics, Inc. | Halo-dehydro-3'-deoxyuracil phosphoramidates and related compounds and their use in treating medical conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0104168D0 (en) * | 2001-02-20 | 2001-04-11 | European Molecular Biology Lab Embl | Disease model |
| CA2986891C (en) * | 2015-05-26 | 2022-01-04 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Compositions for use in treating parkinson's disease and related disorders |
| MX2021008751A (es) * | 2019-01-25 | 2021-11-12 | Univ Brown | Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad. |
| US20220160710A1 (en) * | 2019-03-08 | 2022-05-26 | University Of Virginia Patent Foundation | Compositions and methods for treating or preventing alzheimer's disease |
| IL301564A (en) * | 2020-09-23 | 2023-05-01 | Transposon Therapeutics Inc | LINE-1 inhibitors to treat the disease |
-
2022
- 2022-06-03 AU AU2022283915A patent/AU2022283915A1/en active Pending
- 2022-06-03 KR KR1020247000214A patent/KR20240017910A/ko active Pending
- 2022-06-03 MX MX2023014381A patent/MX2023014381A/es unknown
- 2022-06-03 IL IL309036A patent/IL309036A/en unknown
- 2022-06-03 US US18/566,413 patent/US20240285664A1/en active Pending
- 2022-06-03 CN CN202280048917.1A patent/CN117813096A/zh active Pending
- 2022-06-03 CA CA3221190A patent/CA3221190A1/en active Pending
- 2022-06-03 EP EP22816917.3A patent/EP4346835A4/en active Pending
- 2022-06-03 JP JP2023574354A patent/JP2024520132A/ja active Pending
- 2022-06-03 WO PCT/US2022/032120 patent/WO2022256625A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240017910A (ko) | 2024-02-08 |
| EP4346835A4 (en) | 2025-04-16 |
| JP2024520132A (ja) | 2024-05-21 |
| US20240285664A1 (en) | 2024-08-29 |
| MX2023014381A (es) | 2023-12-15 |
| AU2022283915A1 (en) | 2024-01-18 |
| CA3221190A1 (en) | 2022-12-08 |
| WO2022256625A1 (en) | 2022-12-08 |
| CN117813096A (zh) | 2024-04-02 |
| EP4346835A1 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4262803A4 (en) | Tetrahydropyridopyrimidine pan-kras inhibitors | |
| EP4216951A4 (en) | KRAS G12D INHIBITORS | |
| EP4197538A4 (en) | Egfr inhibitor | |
| EP4083038A4 (en) | PYRIDAZINYL THIAZOLECARBOXAMIDE COMPOUND | |
| EP4434979A4 (en) | KIF18A INHIBITOR | |
| EP4107782A4 (en) | MICROARRAYS | |
| EP4440587A4 (en) | MICROBIAL CONSORTIUMS | |
| EP4512238A4 (en) | TRANSPORT DEVICE | |
| KR20240099193A9 (ko) | Erbb 억제제로서의 다형체 | |
| EP4346835A4 (en) | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | |
| EP3957265A4 (en) | MICROSCOPE COVER | |
| EP4247372A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4168398A4 (en) | TYK-2 INHIBITOR | |
| EP4063561C0 (en) | REFINER SEGMENT | |
| EP4628384A4 (en) | SPONSORS | |
| EP4226919A4 (en) | FERROPTOSIS INHIBITOR | |
| EP4210694A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4178620A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4643828A4 (en) | Conveyor | |
| IL315728A (en) | Targeted delivery | |
| CL2023000728A1 (es) | Compuestos y composiciones como inhibidores de sppl2a. | |
| EP4043963C0 (de) | Verbessertes ausbleichen | |
| EP3920340C0 (de) | Betätigungsclip | |
| TWI926086B (zh) | 張線器 | |
| EP4448515A4 (en) | PLPRO INHIBITORS |